This Means War: Identical Labels Recommended For Gilead, AbbVie's HCV Drugs In Europe
Executive Summary
AbbVie and Gilead have won positive recommendations in Europe and matching eight-week dosing labels for their latest hepatitis C combination therapies, Maviret and Vosevi – now it's all about the price.
You may also be interested in...
AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV
FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.
2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Gilead CEO John Milligan, pressured by an analyst, gave a brief rundown of the company's strategic priorities as investors wait for the company to spend its $34bn in cash on revenue-increasing opportunities to offset declining hepatitis C drug sales.